- Home
- AIO vs PHVS Comparison
AIO vs PHVS Comparison
Compare AIO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- PHVS
- Stock Information
- Founded
- AIO 2019
- PHVS 2015
- Country
- AIO United States
- PHVS Netherlands
- Employees
- AIO N/A
- PHVS N/A
- Industry
- AIO Finance/Investors Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AIO Finance
- PHVS Health Care
- Exchange
- AIO Nasdaq
- PHVS Nasdaq
- Market Cap
- AIO 865.4M
- PHVS 894.8M
- IPO Year
- AIO N/A
- PHVS 2021
- Fundamental
- Price
- AIO $24.64
- PHVS $16.49
- Analyst Decision
- AIO
- PHVS Strong Buy
- Analyst Count
- AIO 0
- PHVS 5
- Target Price
- AIO N/A
- PHVS $41.60
- AVG Volume (30 Days)
- AIO 141.5K
- PHVS 39.6K
- Earning Date
- AIO 01-01-0001
- PHVS 04-09-2025
- Dividend Yield
- AIO 9.05%
- PHVS N/A
- EPS Growth
- AIO N/A
- PHVS N/A
- EPS
- AIO N/A
- PHVS N/A
- Revenue
- AIO N/A
- PHVS N/A
- Revenue This Year
- AIO N/A
- PHVS N/A
- Revenue Next Year
- AIO N/A
- PHVS N/A
- P/E Ratio
- AIO N/A
- PHVS N/A
- Revenue Growth
- AIO N/A
- PHVS N/A
- 52 Week Low
- AIO $15.09
- PHVS $15.21
- 52 Week High
- AIO $20.25
- PHVS $28.40
- Technical
- Relative Strength Index (RSI)
- AIO 46.34
- PHVS 36.48
- Support Level
- AIO $25.01
- PHVS $17.01
- Resistance Level
- AIO $25.45
- PHVS $17.94
- Average True Range (ATR)
- AIO 0.44
- PHVS 0.71
- MACD
- AIO -0.05
- PHVS -0.09
- Stochastic Oscillator
- AIO 31.37
- PHVS 17.44
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.